✦ LIBER ✦

Seroconversion ameliorates liver function in patients with chronic active hepatitis B (CAH-B): Results from a randomized, controlled trial

✍ Scribed by Reichen, J.; Malé, P.J.; Chevilli, S.; Gonvers, J.J.; Altorfer, J.; Biihler, H.; Lavanchy, D.; Frey, P.C.

Book ID: 122433171
Publisher: Elsevier Science
Year: 1990
Tongue: English
Weight: 101 KB
Volume: 11
Category: Article
ISSN: 0168-8278
DOI: 10.1016/0168-8278(90)91764-N

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Seroconversion induced by interferon alf

Seroconversion induced by interferon alfa-2b (INTRON A) ameliorates quantitative liver function in patients with chronic hepatitis B

✍ Reichen, J; Lavanchy, D; Frei, P 📂 Article 📅 1990 🏛 Elsevier Science 🌐 English ⚖ 72 KB

A prospective randomized controlled tria

A prospective randomized controlled trial of recombinant alpha interpheron versus no treatment in non A, non B chronic active hepatitis (CAH) : Preliminary results

✍ Hespanhol, V.; Parente, B.; Araújo, A.; Cunha, J.; Fernandes, A.; Figueiredo, M. 📂 Article 📅 1988 🏛 Elsevier Science 🌐 English ⚖ 77 KB

A randomized controlled trial of thymope

A randomized controlled trial of thymopentin therapy in patients with chronic hepatitis B

✍ Giovanna Fattovich; Giuliano Giustina; Alfredo Alberti; Maria Guido; Patrizia Po 📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 470 KB

PP-117 Thymosin alpha-1 therapy in Chine

PP-117 Thymosin alpha-1 therapy in Chinese patients with chronic hepatitis B: results from a randomized controlled clinical trial

✍ Lin Zhuang; Jing You; Hong-Ying Chen; Bao-Zhang Tang; Meng-Ling Huang; Yong-Lian 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 56 KB

Efficacy of thymosin α1 in patients with

Efficacy of thymosin α1 in patients with chronic hepatitis B: A randomized, controlled trial

✍ Rong-Nan Chien; Yun-Fan Liaw; Tse-Ching Chen; Chau-Ting Yeh; I.-Shyan Sheen 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 107 KB 👁 1 views

Thymosin ␣ 1 (T␣) is an immune modifier that has been shown in a pilot study to be effective for chronic hepatitis B; this requires confirmation. Ninety-eight patients with clinicopathologically proven chronic hepatitis B were randomly allocated to 3 groups: 1) group A received a 26-week course of T

A randomized controlled trial of lymphob

A randomized controlled trial of lymphoblastoid interferon-α in patients with chronic hepatitis B lacking HBeAg

✍ Giovanna Fattovich; Patrizia Farci; Massimo Rugge; Lucio Brollo; Antonella Manda 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 641 KB

Ongoing hepatitis B virus replication in the presence of antibody to HBeAg can be observed in patients with active liver disease. These forms of chronic hepatitis B have been described as having a poor prognosis. We have conducted a randomized controlled trial to assess the efficacy of lymphoblastoi